Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to examine the effect of denosumab on lumbar spine bone
mineral density (BMD) after one year of treatment in newly transplanted renal allograft
recipients. Secondary endpoints include BMD changes at the total hip and the femoral neck,
changes in body height, changes in bone mineral metabolism parameters, incidence of
fractures, and allograft function at one year. Safety measurements include the occurrence of
rejection episodes, infectious complications, graft loss and mortality.
- Trial with medicinal product